XOMA Royalty Corporation
$ 41.69
0.00%
02 Jun - close price
- Market Cap 522,836,000 USD
- Current Price $ 41.69
- High / Low $ 41.72 / 41.45
- Stock P/E 26.55
- Book Value 7.07
- EPS 1.57
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.34 %
- 52 Week High 42.81
- 52 Week Low 22.29
About
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and Asia Pacific. The company is headquartered in Emeryville, California.
Analyst Target Price
$39.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-18 | 2025-11-12 | 2025-08-13 | 2025-05-13 | 2025-03-17 | 2024-11-07 | 2024-08-13 | 2024-05-09 | 2024-03-08 | 2023-11-07 | 2023-08-08 |
| Reported EPS | 0.173 | 0.08 | 0.7 | 0.44 | 0.06 | -0.06 | -1.59 | 0.84 | -0.86 | -0.49 | -0.6 | -0.59 |
| Estimated EPS | -0.055 | -0.09 | -0.04 | -0.15 | -0.27 | -0.3033 | -0.41 | -0.27 | -0.81 | -0.36 | -0.48 | -0.52 |
| Surprise | 0.228 | 0.17 | 0.74 | 0.59 | 0.33 | 0.2433 | -1.18 | 1.11 | -0.05 | -0.13 | -0.12 | -0.07 |
| Surprise Percentage | 414.5455% | 188.8889% | 1850% | 393.3333% | 122.2222% | 80.2176% | -287.8049% | 411.1111% | -6.1728% | -36.1111% | -25% | -13.4615% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.18 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XOMA
2026-05-18 13:09:33
XOMA Royalty Corporation has updated the structure of its acquisition by Ligand Pharmaceuticals by adding a new wholly-owned subsidiary, XOMA Royalty Holdings Corporation (HoldCo), to facilitate a holding company reorganization under Nevada law. This amendment to the merger agreement, signed on May 16, 2026, involves HoldCo merging with Flex Merger Sub, Inc. to become a subsidiary of Ligand. The company advises stockholders to review forthcoming proxy statements for detailed terms and to inform their voting decision on the proposed acquisition.
2026-05-02 01:10:05
Ligand Pharmaceuticals has announced a takeover plan for XOMA Royalty Corporation, acquiring a 47.0% stake through voting and support agreements. The deal, filed on May 1, 2026, involves Ligand purchasing XOMA for $39 per share in cash plus contingent value rights. This acquisition positions Ligand, known for aggregating royalty-producing drug assets, to expand its portfolio.
2026-05-01 22:10:05
Morgan Stanley analyst Sanjit Singh downgraded Appian Corp (APPN) from Overweight to Equal-Weight, cutting its price target from $41 to $25. Additionally, HC Wainwright & Co. analyst Joseph Pantginis downgraded XOMA Royalty Corp (XOMA) from Buy to Neutral with a $39 price target. These are two significant analyst downgrades announced on Thursday.
2026-04-28 17:40:00
The Schall Law Firm is investigating potential breaches of fiduciary duty by the directors and management of XOMA Royalty Corporation following the company's announcement of its acquisition by Ligand Pharmaceuticals for $739 million. Shareholders of XOMA are encouraged to participate in this investigation to determine if their rights have been violated.
2026-04-28 05:08:58
Ligand Pharmaceuticals has announced its definitive agreement to acquire XOMA Royalty Corporation for approximately $739 million in cash at $39.00 per share. This acquisition is expected to significantly expand Ligand's royalty portfolio to over 200 assets, including seven new commercial products, and is projected to be immediately accretive to Ligand's adjusted EPS in 2026 and by $1.50 per share in 2027. The deal aims to strengthen and diversify Ligand's long-term growth in the biopharma royalty aggregation space.
2026-04-28 05:08:58
Ademi LLP is investigating whether XOMA Royalty Corporation is securing a fair price for its public shareholders in its proposed transaction. The firm is examining if XOMA's board and management have upheld their fiduciary duties and if the transaction terms are equitable. Public shareholders are encouraged to contact the law firm for more information regarding their potential rights.
